Dawnrays Pharmaceutical (Holdings) (HKSE:02348) EPS (Basic): HK$0.15 (TTM As of Dec. 2025)


HKSE:02348 Dawnrays Pharmaceutical (Holdings) Ltd HKSE:02348
80 GF Score
Price HK$0.99
GF Value HK$1.30
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Dawnrays Pharmaceutical (Holdings) EPS (Basic)?

Dawnrays Pharmaceutical (Holdings) HKSE:02348 -2.94% 80 EPS (Basic) is HK$0.15 as of Dec. 2025. GuruFocus rates HKSE:02348 with a GF Score™ of 80/100 and a GF Value™ of HK$1.30 (Modestly Undervalued). The stock has 4 warning signs investors should review.

Dawnrays Pharmaceutical (Holdings)'s basic earnings per share (Basic EPS) for the six months ended in Dec. 2025 was HK$0.08. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Dec. 2025 was HK$0.15.

Dawnrays Pharmaceutical (Holdings)'s EPS (Diluted) for the six months ended in Dec. 2025 was HK$0.08. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was HK$0.15.

Dawnrays Pharmaceutical (Holdings)'s EPS without NRI for the six months ended in Dec. 2025 was HK$0.11. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2025 was 0.21.

During the past 12 months, Dawnrays Pharmaceutical (Holdings)'s average EPS without NRIGrowth Rate was -18.30% per year. During the past 3 years, the average EPS without NRI Growth Rate was -5.50% per year. During the past 5 years, the average EPS without NRI Growth Rate was 0.40% per year. During the past 10 years, the average EPS without NRI Growth Rate was 1.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Dawnrays Pharmaceutical (Holdings)'s highest 3-Year average EPS without NRI Growth Rate was 36.70% per year. The lowest was -17.50% per year. And the median was 5.00% per year.

Dawnrays Pharmaceutical (Holdings)  (HKSE:02348) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Dawnrays Pharmaceutical (Holdings) EPS (Basic) Related Terms

Dawnrays Pharmaceutical (Holdings) EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Dawnrays Pharmaceutical (Holdings)'s EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Dawnrays Pharmaceutical (Holdings) EPS (Basic) Chart

Dawnrays Pharmaceutical (Holdings) Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.29 0.27 0.24 0.41 0.16

Dawnrays Pharmaceutical (Holdings) Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.05 0.35 0.06 0.08 0.08
HKSE:02348
80GF Score
Dawnrays Pharmaceutical (Holdings) Ltd HKSE:02348
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Dawnrays Pharmaceutical (Holdings) EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Dawnrays Pharmaceutical (Holdings)'s Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as

Basic EPS (A: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(236.379-0)/1502.754
=0.16

Dawnrays Pharmaceutical (Holdings)'s Basic EPS for the quarter that ended in Dec. 2025 is calculated as

Basic EPS (Q: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(120.856-0)/1503.309
=0.08

EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$0.15

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of HK$0.15 mean?
Dawnrays Pharmaceutical (Holdings) (HKSE:02348) has a EPS (Basic) of HK$0.15 as of Dec. 2025. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Dawnrays Pharmaceutical (Holdings) and its competitors.
Is Dawnrays Pharmaceutical (Holdings)'s EPS (Basic) too high?
Dawnrays Pharmaceutical (Holdings)'s current EPS (Basic) is HK$0.15. Overall, Dawnrays Pharmaceutical (Holdings) has a GF Score™ of 80/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Dawnrays Pharmaceutical (Holdings)'s EPS (Basic) compare to ZTS?
Dawnrays Pharmaceutical (Holdings)'s EPS (Basic) of HK$0.15 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Drug Manufacturers company?
A good EPS (Basic) depends on the Drug Manufacturers industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Dawnrays Pharmaceutical (Holdings) and its competitors. Dawnrays Pharmaceutical (Holdings)'s current EPS (Basic) is HK$0.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dawnrays Pharmaceutical (Holdings) stock overvalued right now?
Based on GuruFocus' analysis, Dawnrays Pharmaceutical (Holdings) (HKSE:02348) is currently considered Modestly Undervalued. The stock's GF Value™ is HK$1.30, compared to a current price of HK$0.99 — trading 23.8% below its estimated fair value. The current EPS (Basic) is HK$0.15. Dawnrays Pharmaceutical (Holdings)'s overall GF Score™ is 80/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Dawnrays Pharmaceutical (Holdings) (HKSE:02348), the current EPS (Basic) is HK$0.15 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Dawnrays Pharmaceutical (Holdings) (HKSE:02348) Overvalued in 2026?

Based on GuruFocus' analysis, Dawnrays Pharmaceutical (Holdings) stock appears to be undervalued. The current stock price of HK$0.99 is trading 23.8% below its estimated GF Value™ of HK$1.30. GuruFocus considers Dawnrays Pharmaceutical (Holdings) to be Modestly Undervalued.

Key valuation signals for HKSE:02348:

  • EPS (Basic): HK$0.15
  • GF Value™: HK$1.30 vs. price of HK$0.99 (23.8% below fair value)
  • GF Score™: 80/100 with 4 warning signs

No single metric tells the full story. See the HKSE:02348 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Dawnrays Pharmaceutical (Holdings) Business Description

Address 338 Hennessy Road, Units 3001-02, 30th Floor, CNT Tower, Wanchai, North Sea Centre, Hong Kong, HKG
Dawnrays Pharmaceutical (Holdings) Ltd is a drug manufacturing company. The company operates two segments, Manufacture and sale of finished drugs and Manufacture and sale of intermediates and bulk medicines. The revenue is derived from the Finished Drugs segment. Nearly all of the company's sales are generated in Mainland China. It utilizes strategic partnerships as a component of its international strategies. The company is open to exploring potential acquisitions as a component of its overall growth plan.
80GF Score

Get the complete analysis for HKSE:02348

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$0.99
Price
HK$1.30
GF Value